蓝丰生化(002513) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥445,348,860.72, a decrease of 10.98% compared to the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥28,721,582.20, representing a decline of 239.78% year-over-year[4]. - The net profit after deducting non-recurring gains and losses was a loss of ¥29,772,640.99, down 582.69% from the previous year[4]. - The company reported a net loss of ¥14,675,245.26, compared to a net profit of ¥2,023,237.18 in the same period last year, indicating a significant decline in profitability[24]. - The total comprehensive income for the third quarter was -42,229,317.91 CNY, compared to 10,849,342.85 CNY in the previous period[25]. - Basic and diluted earnings per share were both -0.12 CNY, down from 0.030 CNY in the previous period[25]. Cash Flow and Liquidity - The operating cash flow for the year-to-date period was ¥57,873,864.42, an increase of 108.44%[4]. - Cash inflow from operating activities totaled 1,163,764,621.92 CNY, an increase from 1,014,064,509.71 CNY year-over-year[28]. - The net cash flow from operating activities was 57,873,864.42 CNY, compared to 27,765,369.26 CNY in the previous period[28]. - Cash received from tax refunds increased by 119.17% to ¥49,020,242.25 due to an increase in export tax rebates[11]. - Cash paid for various taxes decreased by 61.91% to ¥5,720,956.85 as Ark Pharmaceutical was no longer included in the consolidation scope[11]. - Cash received from borrowings decreased by 62.63% to ¥82,000,000.00 due to reduced borrowings from financial institutions[11]. - The cash and cash equivalents at the end of the period were 95,348,563.04 CNY, compared to 76,480,304.41 CNY at the end of the previous period[29]. - The company received 82,000,000.00 CNY in borrowings during the period, down from 219,455,000.00 CNY in the previous period[29]. - The company reported a cash inflow of 136,000,000.00 CNY from financing activities, a decrease from 307,918,167.57 CNY in the previous period[29]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,175,101,420.34, a decrease of 5.88% from the end of the previous year[4]. - The total assets decreased to ¥2,175,101,420.34 from ¥2,311,049,219.02, reflecting a reduction of approximately 5.9%[22]. - Current liabilities totaled ¥1,043,374,503.37, down from ¥1,133,924,366.46, representing a decrease of about 7.9%[21]. - The total liabilities decreased to ¥1,058,356,632.50 from ¥1,151,139,145.31, a reduction of approximately 8.1%[21]. - The company’s retained earnings showed a negative balance of ¥1,098,080,958.30, worsening from a negative balance of ¥1,055,851,640.39 in the previous period[22]. Operational Metrics - Total operating revenue for the period reached ¥1,085,671,226.21, a slight increase of 0.1% compared to ¥1,078,645,108.88 in the previous period[23]. - Total operating costs amounted to ¥1,143,331,222.90, up 4.7% from ¥1,092,088,741.15 in the prior period, with operating costs specifically rising from ¥923,023,103.14 to ¥1,010,574,300.94[23]. - The company reported a significant decrease in sales expenses by 56.18% to ¥24,103,059.75, primarily due to the exclusion of Ark Pharmaceutical from the consolidation scope[10]. - Research and development expenses were reported at ¥11,010,052.54, a decrease from ¥12,201,817.24, indicating a reduction of about 9.8%[23]. Changes in Financial Structure - The company's cash and cash equivalents decreased by 48.73% to ¥169,933,876.22 due to increased loan repayments[8]. - Accounts receivable increased by 115.59% to ¥105,250,946.83, attributed to increased credit sales[8]. - Contract liabilities rose by 181.17% to ¥95,174,510.00, indicating an increase in advance payments received[8]. - The company did not adjust the initial balance sheet items due to the new leasing standards, indicating no significant impact on financial status and operating results[30]. - Cash paid for the acquisition of fixed assets increased by 86.77% to ¥92,669,182.62, attributed to payments for fixed asset purchases[11]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,817[14]. - The company registered a new wholly-owned subsidiary with a registered capital of ¥2 million, focusing on pesticide wholesale and retail, and crop seed import and export[16].